mtgayhealth.org

As cheaper, generic versions of Truvada made by Mylan NV, Cipla Ltd. and Teva Pharmaceutical Industries Ltd. become more widely available, doctors and public health researchers are testing its ability to slash HIV incidence in the developing world, especially sub-Saharan Africa, where it’s mostly transmitted by heterosexual sex. The global epidemic is driven in eastern and southern Africa, and it’s driven predominantly among women,” said Mitchell Warren, executive director of New York-based advocacy group AVAC, which tracks more than 40 ongoing and planned PrEP studies across the world. While “PrEP appeared to be effective in reducing the transmission of HIV,” Truvada wasn’t cost-effective at the price Gilead requested, the Pharmaceutical Benefits Advisory Committee said in a statement Friday. Based on a health department survey, about 30 percent of men ages 18 to 40 who have sex with men are on PrEP — and the benefits of it outweigh any risks, according to Daskalakis, who calls himself a “queer health warrior” and posed bare-chestedin posters on the New York subway for a campaign in June to encourage citizens to find a new doctor if they can’t talk openly about their sex lives.

This weekend, Goldtooth is among 70 Native Americans from tribes across the continent — from Alberta, Delaware, Georgia, Oklahoma, New Mexico, Montana, Idaho, and Washington — who are converging for the Montana Two Spirit Society’s annual gathering. The delineation seems to be people who live in more traditional areas and people who are more urban and Christianized,” he says. I said, ‘This term was coined for our Native American people, and it’s a shame you can’t look into your own history and find a word for yourself. But I like to imagine what it was like for the people living here among the rocks when they didn’t have light.

There is now evidence-based confirmation that the risk of HIV transmission from a person living with HIV (PLHIV), who is on Antiretroviral Therapy (ART) and has achieved an undetectable viral load in their blood for at least 6 months is negligible to non-existent. The consensus statement below, addressing HIV transmission risk from PLHIV who have an undetectable viral load, is endorsed by principal investigators from each of the leading studies that examined this issue. At the same time, it is important to recognize that many PLHIV may not be in a position to reach an undetectable status because of factors limiting treatment access (e.g., inadequate health systems, poverty, racism, denial, stigma, discrimination, and criminalization), pre-existing ART treatment resulting in resistance or ART toxicities. Understanding that successful ART prevents transmission can help reduce HIV-related stigma and encourage PLHIV to initiate and adhere to a successful treatment regimen.